Get started
Author

Julien Grogg

Observed names: Grogg, J., Grogg, Julien, J. Grogg, J.B. Grogg
ORCID: 0000-0002-9479-0933
Observed ORCID: 0000-0002-9479-0933
OpenAlex ID: A5050485398
A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein
2021 · Rémi Vernet, Emily Charrier, et al. · Vaccines · 19
PDF
MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology
2016 · N. Mach, R. Vernet, et al. · Annals of Oncology · 15
Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology
2022 · Aurelien Lathuiliere, Remi Vernet, et al. · Molecular Therapy — Methods & Clinical Development · 14
PDF
MVX-ONCO-1 in advanced refractory cancers: Safety, feasibility, and preliminary efficacy results from all HNSCC patients treated in two ongoing clinical trials.
2021 · Eugenio Fernandez, Remi Vernet, et al. · Journal of Clinical Oncology · 10
A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al. · Cancer Research Communications · 8
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial
2025 · Eugenio Fernandez, Rémi Vernet, et al. · Experimental Hematology and Oncology · 6
PDF
Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins
2023 · Julien Grogg, Remi Vernet, et al. · iScience · 6
PDF
Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model
2021 · Rémi Vernet, Emily Charrier, et al. · Vaccines · 6
PDF
531 MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results
2015 · D. Migliorini, R. Vernet, et al. · European Journal of Cancer · 4
Abstract 2721: Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model
2023 · Julien Grogg, Emily Charrier, et al. · Cancer Research · 2
PDF
Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from first in man trial
2015 · N. Mach, D. Migliorini, et al. · Annals of Oncology · 2
PDF
Table 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al. · 1
Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology
2023 · Aurelien Lathuiliere, Remi Vernet, et al. · Molecular Therapy — Methods & Clinical Development · 1
Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy
2026 · Adrien Engel, Remi Vernet, et al. · iScience
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial
2025 · Fernandez, Eugenio, Vernet, Rémi, et al. · Zurich Open Repository and Archive (University of Zurich)
Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2025 · Rémi Vernet, Eugenio Fernandez, et al.
Cell-based device provides effective therapeutic strategy to treat the metachromatic leukodystrophy
2025 · Elena Gaia Banchi, Rafael Alonso, et al. · Molecular Genetics and Metabolism
59P Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
2024 · N. Mach, E. Fernandez, et al. · Immuno-Oncology Technology
PDF
Data from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al.
Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al.
Table 1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al.
Figure 5 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al.
Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al.
Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al.
Figure 2 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
2024 · Rémi Vernet, Eugenio Fernandez, et al.
Works count: 36
Citation count: 94
H-index: 6
I10-index: 4
Year
Topic
Type